The stock price of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has increased significantly, with shares rising 19.45% to $2.21 in the current market. This growing trend confirms MIRA’s status as a pioneer in cutting-edge medicines and comes after the release of a ground-breaking finding in the management of neuropathic pain.
MIRA Pharmaceuticals’ Highlights Breakthrough Efficacy
In a recent pre-clinical study conducted on rats, MIRA Pharmaceuticals unveiled that its novel oral ketamine analog, Ketamir-2, exhibited remarkable efficacy in reversing neuropathic pain. Utilizing a nerve ligation model at Pharmaseed Ltd, the study sought to mimic human neuropathic pain and focused specifically on mechanical allodynia.
The results were compelling: Ketamir-2 not only reduced pain significantly at low doses but also achieved complete normalization of pain thresholds at higher doses, marking a 100% reversal of the neuropathic pain signal. This finding is particularly significant when contrasted with traditional oral ketamine, which failed to deliver similar results under the same conditions.
Future Studies and Potential Implications
Encouraged by these promising results, MIRA Pharmaceuticals is advancing its research to assess Ketamir-2’s potential in treating other conditions, including cancer-induced depression and neuropathic pain. With the potential to show efficacy in human trials as early as 2025, the business is confident that these investigations might result in quicker regulatory approvals and creative clinical research designs.
MIRA Revolutionizing the Standard of Care for Neuropathic Pain
The successful development of ketamir-2 represents a significant advancement for both MIRA Pharmaceuticals and the broader field of neurologic and neuropsychiatric drug research. Many patients have considerable reductions in quality of life due to neuropathic pain, which has historically been linked to few and frequently ineffective therapeutic choices.
The research conducted by MIRA Pharmaceuticals indicates that Ketamir-2 may provide a safer, more readily available, and more efficacious substitute, which has the potential to revolutionize the current standard of treatment. Moreover, the ability to administer Ketamir-2 orally without the severe psychotropic side effects typically associated with ketamine underscores its potential as a pioneering treatment, offering renewed hope to patients with few therapeutic options.
